Whilst greater EGF receptor prevalence is associated with multiple cancer types (Fisher et al. 2018; Gao et al. 2016; Tokunaga et al. 1995), cardiovascular disease (Makki et al. 2013), and in vitro EGF has been shown to influence cellular proliferation and differentiation rates [included in C2C12 myocytes (Ciano et al. 2019)], it is difficult to speculate concerning the biological role that post-SIT EGF suppression exerts in older men here. The gene discussed is EGF; the disease is cancer.